NCT03145766View on ClinicalTrials.gov

Immunogenicity and Safety of a Purified Vero Rabies Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

January 8, 2018

Study Completion Date

January 8, 2018

Conditions
Rabies Virus
Interventions
BIOLOGICAL

VRVg 2

Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free

BIOLOGICAL

VRVg 1

Initial formulation of Purified Vero Rabies Vaccine Serum Free

BIOLOGICAL

Imovax Rabies

Purified inactivated rabies vaccine prepared on human diploid cell cultures

BIOLOGICAL

VRVg 2

Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free

BIOLOGICAL

VRVg 2

Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free

BIOLOGICAL

Human Rabies Immunoglobulins (HRIG)

Commercialized formulation of HRIG

Trial Locations (5)

33143

Investigational Site, South Miami

68134

Investigational Site, Omaha

89104

Investigational Site, Las Vegas

92117

Investigational Site, San Diego

96001

Investigational Site, Redding

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03145766 - Immunogenicity and Safety of a Purified Vero Rabies Vaccine | Biotech Hunter | Biotech Hunter